FDA Approves Aptivus for HIV Infection
Aptivus (tipranavir) is a non-peptidic protease inhibitor that works by inhibiting protease, an enzyme needed to complete the HIV replication process. Aptivus, co-administered with 200 mg of ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.Posted: June 2005
Related articles
- New Aptivus (tipranavir) Oral Solution Approved forTreatment-Experienced Pediatric and Adolescent HIV Patients - June 24, 2008
- Aptivus (tipranavir) Capsules Granted Full Approval by the U.S. FDA - October 5, 2007
- FDA Antiviral Drugs Advisory Committee Recommends Accelerated Approval for Investigational Anti-HIV Drug Tipranavir - May 19, 2005
- Boehringer Ingelheim Submits New Drug Application to U.S. Food and Drug Administration for Tipranavir - October 25, 2004
Aptivus (tipranavir) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
